Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HIV Drug Project Would Aim For A Cure

This article was originally published in The Pink Sheet Daily

Executive Summary

Industry/government/academia collaboration would produce a new portfolio of drugs to eradicate the virus from tissue reservoirs where it lies latent, providing possible drug-free remission and potentially a cure:

You may also be interested in...



Infectious Diseases Space Wide Open For Partnering Beyond Hep C, Conference Finds

The recent spotlight on hepatitis C doesn't mean that's the only hot area in infectious diseases for deals.

Infectious Diseases Space Wide Open For Partnering Beyond Hep C, Conference Finds

The recent spotlight on hepatitis C doesn't mean that's the only hot area in infectious diseases for deals.

J&J’s Intelence Approved For HIV Treatment In NNRTI-Resistant Patients

Johnson & Johnson’s Tibotec unit prices etravirine at wholesale acquisition cost of $5.45, firm tells “The Pink Sheet” DAILY.

Topics

UsernamePublicRestriction

Register

PS069160

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel